This Article Full Text Full Text (PDF) Online Supplement All Versions of this Article: 200501-114OCv1 172/9/1105    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Vliet, M. Articles by Decramer, M. Search for Related Content PubMed PubMed Citation Articles by Van Vliet, M. Articles by Decramer, M.

Hypogonadism, Quadriceps Weakness, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease

Respiratory Rehabilitation and Respiratory Division, University Hospital Gasthuisberg; Department of Rehabilitation Sciences, Faculty of Kinesiology and Rehabilitation Sciences; and Laboratories of Pneumology, Experimental Immunology, and Experimental Medicine and Endocrinology (LEGENDO), Faculty of Medicine, Katholieke Universiteit Leuven, Leuven, Belgium

Correspondence and requests for reprints should be addressed to Marc Decramer, Ph.D., M.D., Respiratory Rehabilitation, University Hospital Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium. E-mail address: marc.decramer{at}uz.kuleuven.ac.be

Rationale: Circulating levels of testosterone and gonadotrophins of patients with chronic obstructive pulmonary disease (COPD) have never been compared with those of elderly men with normal pulmonary function. Moreover, the relationship of hypogonadism with quadriceps muscle weakness and exercise intolerance has been studied scarcely in men with COPD.

Objectives: To compare circulating levels of hormones of the pituitary–gonadotrophic axis of men with COPD with those of age-matched control subjects. Moreover, to study the relationship of hypogonadism with quadriceps muscle force, 6-min walking distance, and systemic markers of inflammation in the patients.

Methods and Measurements: Circulating levels of follicle-stimulating hormone, luteinizing hormone, testosterone, and sex homone–binding globulin were determined, and free testosterone was calculated in 78 patients (FEV₁: 44 ± 17% of the predicted values) and 21 control subjects. Moreover, quadriceps muscle force, 6-min walking distance, number of pack-yr, and systemic inflammation were determined.

Main Results: Follicle-stimulating hormone and luteinizing hormone were higher in the patients, whereas testosterone was lower (p 0.05). The latter finding was also present in 48 non–steroid-using patients with normal blood gases. Low androgen status was significantly related to quadriceps muscle weakness (r = 0.48) and C-reactive protein (r = –0.39) in the patients, but not to exercise intolerance, the number of pack-yr, or increased circulating levels of interleukin 8 or soluble receptors of tumor necrosis factor .

Conclusions: In contrast to exercise intolerance, quadriceps muscle weakness is related to low circulating levels of testosterone in men with COPD.

Key Words: follicle-stimulating hormone • luteinizing hormone • quadriceps muscle strength • sex hormone–binding globulin • testosterone

This article has been cited by other articles:

				L. Graat-Verboom, E. F. M. Wouters, F. W. J. M. Smeenk, B. E. E. M. van den Borne, R. Lunde, and M. A. Spruit Current status of research on osteoporosis in COPD: a systematic review Eur. Respir. J., July 1, 2009; 34(1): 209 - 218. [Abstract] [Full Text] [PDF]

				C. Bolton, M. Stone, P. Edwards, J. Duckers, W. Evans, and D. Shale Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease Chronic Respiratory Disease, May 1, 2009; 6(2): 81 - 87. [Abstract] [PDF]

				B. TENGSTRAND, K. CARLSTROM, and I. HAFSTROM Gonadal Hormones in Men with Rheumatoid Arthritis -- From Onset Through 2 Years J Rheumatol, May 1, 2009; 36(5): 887 - 892. [Abstract] [Full Text] [PDF]

				P. J. Barry, D. F. Waterhouse, C. M. Reilly, T. J. McKenna, E. F. McKone, and C. G. Gallagher Androgens, Exercise Capacity, and Muscle Function in Cystic Fibrosis Chest, December 1, 2008; 134(6): 1258 - 1264. [Abstract] [Full Text] [PDF]

				M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]

				A. B. Araujo, V. Kupelian, S. T. Page, D. J. Handelsman, W. J. Bremner, and J. B. McKinlay Sex Steroids and All-Cause and Cause-Specific Mortality in Men Arch Intern Med, June 25, 2007; 167(12): 1252 - 1260. [Abstract] [Full Text] [PDF]

				A. L. Ries, G. S. Bauldoff, B. W. Carlin, R. Casaburi, C. F. Emery, D. A. Mahler, B. Make, C. L. Rochester, R. ZuWallack, and C. Herrerias Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines Chest, May 1, 2007; 131(5_suppl): 4S - 42S. [Abstract] [Full Text] [PDF]

				L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF]

				F. Laghi Low Testosterone in Chronic Obstructive Pulmonary Disease: Does It Really Matter? Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1069 - 1070. [Full Text] [PDF]